U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H17FN6O
Molecular Weight 412.4199
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAPMATINIB

SMILES

CN=C(c1ccc(cc1F)-c2cnc3ncc(Cc4ccc5c(cccn5)c4)n3n2)O

InChI

InChIKey=LIOLIMKSCNQPLV-UHFFFAOYSA-N
InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

HIDE SMILES / InChI

Molecular Formula C23H17FN6O
Molecular Weight 412.4199
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800031741

Capmatinib (INC280, INCB028060), is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. Novartis acquired Incyte's capmatinib, which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

CNS Activity

Curator's Comment:: INC280 is a highly potent and selective c-MET inhibitor which also penetrates the blood-brain barrier

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6450 ng/mL
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CAPMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
26300 ng × h/mL
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CAPMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.7 h
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CAPMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Other AEs: ALT increased, Nausea...
Other AEs:
ALT increased (grade 3-4, 13%)
Nausea (grade 1-2, 38%)
Vomiting (grade 1-2, 38%)
AST increased (grade 1-2, 25%)
Blood bilirubin increased (grade 1-2, 13%)
Fatigue (grade 1-2, 38%)
Decreased appetite (grade 1-2, 38%)
Peripheral edema (grade 1-2, 13%)
Hypoalbuminemia (grade 1-2, 13%)
Diarrhea (grade 1-2, 25%)
Protein total decreased (grade 1-2, 13%)
Stomatitis (grade 1-2, 13%)
Dyspepsia (grade 1-2, 13%)
Sources:
200 mg 2 times / day steady, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
250 mg 2 times / day steady, oral
Studied dose
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
DLT: Blood bilirubin increased...
Dose limiting toxicities:
Blood bilirubin increased (grade 3, 1 patient)
Sources:
450 mg 2 times / day steady, oral
Studied dose
Dose: 450 mg, 2 times / day
Route: oral
Route: steady
Dose: 450 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Disc. AE: Peripheral edema, Pneumonitis...
AEs leading to
discontinuation/dose reduction:
Peripheral edema (all grades, 1.8%)
Pneumonitis (all grades, 1.8%)
Fatigue (all grades, 1.5%)
Peripheral edema (>2)
Blood creatinine increased (>2)
Nausea (>2)
Vomiting (>2)
Lipase increased (>2)
ALT increased (>2)
Dyspnea (>2)
Amylase increased (>2)
AST increased (>2)
Blood bilirubin increased (>2)
Fatigue (>2)
Pneumonia (>2)
Sources:
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Disc. AE: Peripheral edema, Pneumonitis...
AEs leading to
discontinuation/dose reduction:
Peripheral edema (grade 3-4, 0.6%)
Pneumonitis (grade 3-4, 0.3%)
Fatigue (grade 3-4, 0.9%)
ALT increased (all grades, 0.9%)
ALT increased (grade 3-4, 0.6%)
AST increased (all grades, 0.9%)
AST increased (grade 3-4, 0.6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blood bilirubin increased grade 1-2, 13%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Dyspepsia grade 1-2, 13%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Hypoalbuminemia grade 1-2, 13%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Peripheral edema grade 1-2, 13%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Protein total decreased grade 1-2, 13%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Stomatitis grade 1-2, 13%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
AST increased grade 1-2, 25%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Diarrhea grade 1-2, 25%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Decreased appetite grade 1-2, 38%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Fatigue grade 1-2, 38%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Nausea grade 1-2, 38%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Vomiting grade 1-2, 38%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
ALT increased grade 3-4, 13%
600 mg 2 times / day steady, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Fatigue grade 3, 1 patient
DLT
200 mg 2 times / day steady, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Blood bilirubin increased grade 3, 1 patient
DLT
250 mg 2 times / day steady, oral
Studied dose
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
Fatigue grade 3, 1 patient
DLT
450 mg 2 times / day steady, oral
Studied dose
Dose: 450 mg, 2 times / day
Route: oral
Route: steady
Dose: 450 mg, 2 times / day
Sources:
unhealthy, 56.0 years
Health Status: unhealthy
Age Group: 56.0 years
Sex: M+F
Sources:
ALT increased >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
AST increased >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Amylase increased >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Blood bilirubin increased >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Blood creatinine increased >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Dyspnea >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Fatigue >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Lipase increased >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Nausea >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Peripheral edema >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Pneumonia >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Vomiting >2
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Fatigue all grades, 1.5%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Peripheral edema all grades, 1.8%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Pneumonitis all grades, 1.8%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
ALT increased all grades, 0.9%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
AST increased all grades, 0.9%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Pneumonitis grade 3-4, 0.3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
ALT increased grade 3-4, 0.6%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
AST increased grade 3-4, 0.6%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Peripheral edema grade 3-4, 0.6%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Fatigue grade 3-4, 0.9%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 71 years (range: 49 - 90 years)
Health Status: unhealthy
Age Group: 71 years (range: 49 - 90 years)
Sex: M+F
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak [Ki 0.9 uM]
likely
Comment: capmatinib was predicted to be a weak CYP2C8 inhibitor with 23% increase in Cmax and 39% increase in AUC of repaglinide
Page: 86, 88, 200, 202
yes [EC50 39.4 uM]
yes [Ki 0.28 uM]
yes [Ki 0.29 uM]
yes [Ki 3 uM]
unlikely
Comment: no significant exposure change was predicted for warfarin
Page: 86, 200, 202
yes [Ki 4.3 uM]
no (co-administration study)
Comment: In subjects with cancer, co-administration of midazolam (a sensitive CYP3A4 substrate) with multiple doses of capmatinib (400 mg b.i.d.) did not cause any clinically significant increase in midazolam exposure compared to administration of midazolam alone.
Page: 87, 200, 202
yes [Ki 6.1 uM]
unlikely
Comment: no significant exposure change was predicted for omeprazole
Page: 86, 200, 202
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: coadministration with rosuvastatin increased rosuvastatin AUC by 108% and Cmax by 204%
Page: 86, 88, 200
yes
yes (co-administration study)
Comment: coadministration with digoxin increased digoxin AUC by 47% and Cmax by 74%
Page: 86, 88
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes (co-administration study)
Comment: itraconazole increased capmatinib exposure 42%; rifampicin decreased capmatinib exposure by 67% and Cmax by 56%
Page: 66, 75, 83, 85
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

400 mg twice every day by mouth, continuously
Route of Administration: Oral
Capmatinib inhibits c-MET phosphorylation with an IC50 value of approximately 1 nmol/L and a concentration of approximately 4 nmol/
Substance Class Chemical
Created
by admin
on Sat Jun 26 08:57:27 UTC 2021
Edited
by admin
on Sat Jun 26 08:57:27 UTC 2021
Record UNII
TY34L4F9OZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAPMATINIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
CAPMATINIB [USAN]
Common Name English
INCB-28060 FREE BASE
Code English
INC280
Code English
CAPMATINIB [WHO-DD]
Common Name English
NVP-INC280
Code English
INC-280
Code English
CAPMATINIB [INN]
Common Name English
INCB-28060
Code English
2-FLUORO-N-METHYL-4-(7-(QUINOLIN-6-YLMETHYL)IMIDAZO(1,2-B)(1,2,4)TRIAZIN-2-YL)BENZAMIDE
Systematic Name English
BENZAMIDE, 2-FLUORO-N-METHYL-4-(7-(6-QUINOLINYLMETHYL)IMIDAZO(1,2-B)(1,2,4)TRIAZIN-2-YL)-
Systematic Name English
NVP-INC280-NX
Code English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
NCI_THESAURUS C1742
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
FDA ORPHAN DRUG 644518
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C90564
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
CAS
1029712-80-8
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
FDA UNII
TY34L4F9OZ
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
EPA CompTox
1029712-80-8
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
EVMPD
SUB181273
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
PUBCHEM
25145656
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
RXCUI
2362165
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
ChEMBL
CHEMBL3188267
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
INN
9948
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
DRUG BANK
DB11791
Created by admin on Sat Jun 26 08:57:28 UTC 2021 , Edited by admin on Sat Jun 26 08:57:28 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
REVERSIBLE
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL
TRANSPORTER -> INHIBITOR
REVERSIBLE
EXCRETED UNCHANGED
TRACE AMOUNT
URINE
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
independent of capmatinib concentration
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
MINOR
FECAL; URINE
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
MINOR
FECAL; URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC IN PATIENTS WITH CANCER

ORAL ADMINISTRATION

blood-to-plasma ratio PHARMACOKINETIC at higher concentrations

blood-to-plasma ratio PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC AT STEADY-STATE